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Abstract 
Background: An international shift in healthcare has seen an increasing focus on 
personalised, technology-enabled, in-home health interventions (eHealth interventions) 
that aim to improve patient outcomes and patient-clinician communication. When tested 
on an international scale, the development and effectiveness of such interventions are 
dependent on collaborative work conducted by multidisciplinary teams to address a 
number of methodological and implementation considerations. 
Objective: To describe the processes undertaken in the preparation of an international, 
multi-centre randomised controlled trial that tested an eHealth intervention to enhance 
management of chemotherapy toxicity in people with cancer receiving adjuvant 
chemotherapy, via use of a mobile-phone, remote-monitoring symptom management 
system versus standard hospital care.   
Setting: Thirteen clinical sites across five European countries (Austria, Greece, Ireland, 
Norway, United Kingdom) 
Methods: Prospective, mixed-methods, involving consecutive, iterative stages of 
collaborative research work. 
Results: Testing across multiple European sites identified areas where the technology 
needed to be adapted, both clinically and technologically, in order to meet the diverse 
needs of the users within a European context prior to initiation of the RCT. 
Conclusions: Adapting and implementing this international, multicentre intervention 
required close attention to diverse considerations and unique challenges, primarily time 
and communication. Success was dependent on collaborative work among academics, 
technology industry, patients, and clinicians as well as a rigorous and iterative 
methodological approach to research. 
 
KEYWORDS: multinational research, eHealth, digital health, methodology, 
implementation, cancer, patient related outcomes 
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Introduction 
Background 
The expanding field of electronic health (eHealth) and the global integration of 
technology into healthcare systems [1-4] have become more apparent over the past two 
decades. This leap in technology capabilities has led to many promising eHealth 
advancements in the cancer setting. For instance, an increasing numbers of healthcare 
initiatives in cancer care have utilised ǯself-reports to facilitate remote symptom 
monitoring [5-13].  
 
Despite the research conducted so far, there is a notable lack of empiric evidence 
describing the preparation and implementation of an eHealth intervention across 
multiple countries and clinical sites [14, 15]. This omission may be in part due to the fact 
that eHealth remains a relatively new area of research, that is characterized by 
exploratory studies implementing novel technology in healthcare practice and assessing 
their feasibility in a single-country [16-21].  
 
Conducting cross-cultural, multinational research requires collaboration and multiple 
considerations to ensure an ǯ, fidelity, and appropriateness within 
different cultural and clinical settings [22-24]. The current paper seeks to address this 
important gap in the knowledge within the cancer eHealth literature by describing the 
process that was used to adapt and implement an evidence-based, remote symptom 
monitoring system, ASyMS (Advanced Symptom Management System Remote 
Technology) prior to use in a multicentre European randomised controlled trial (RCT) 
within thirteen clinical centres across five countries (i.e. Norway, Austria, Greece, Ireland, 
United Kingdom). The title of the RCT is electronic Symptom Management using 
Advanced Symptom Management System (ASyMS) Remote Technology for patients with 
cancer, for which the acronym is eSMART [25].    
 
 
The ASyMS intervention 
This international project involves a large RCT that aims to evaluate the short and long-
term impact of a mobile-based, remote monitoring intervention (ASyMS) on symptoms 
in patients receiving first-line chemotherapy for breast cancer, colorectal cancer, or 
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haematological malignancies. The ASyMS intervention utilises mobile device technology 
to enable real-time, 24-hour monitoring and management  ǯ -reported 
chemotherapy-related toxicities (CRTs).   
Patients use a dedicated mobile device to complete a symptom questionnaire 
(Chemotherapy Toxicity Self-Assessment Questionnaire (CTAQ)) which assesses ten 
chemotherapy (CTX) related symptoms (i.e., nausea, vomiting,  diarrhoea, constipation, 
hand-foot syndrome, mucositis, paraesthesia, flu-like symptoms/infection, fatigue, pain 
and up to six additional symptoms) once a day and at any time they feel unwell.  This 
information is analysed by an integrated clinical risk algorithm which results in the 
automated generation of evidence-based, self-care advice to patients on the mobile 
device based on their symptom reports.   
For any reports that require clinical intervention, the algorithm generates Ǯ ǯ 
alerts to the clinical sites via a dedicated clinician handset.  This clinician handset is a 
specialised mobile device used to receive alerts Ǯǯ 
carries this device at all times. Alerts can be either amber (i.e. related to moderate 
symptoms that should be addressed within 8 hours) or red alerts (i.e. severe symptoms 
that should be responded to within a 30-minute timeframe).  
 
Figure 1. Patient Device and Clinician Handset 
 
Once the alert is received, the alert handler views  ǯ Ǯ-ǯ 
reports on a secure stand-alone ASyMS wesbite, before contacting the patient to initiate 
the appropriate care intervention. Alert handlers can access information stored on the 
secure ASyMS website, including ǯǡ
information, contact telephone numbers and addresses to facilitate a clinical assessment 
with the patient. Clinical algorithms that are based on international, national, and local 
guidelines as well as feedback from clinicians and patients determine the appropriate, 
standardised interventions for the type of alert generated. The alert handler documents ǯȀǡ
alert on the ASyMS website. 
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Figure 2. ASyMS Alert Generation and Handling System 
 
Methods 
In preparation for the use of ASyMS within an international, multi-centre randomised 
controlled trial the following steps were undertaken:  
 Review of the literature on the assessment and management of chemotherapy-related 
toxicity to ensure ASyMS reflected national guidelines and international best practice.  
 
 Translate and linguistically validate the assessment questionnaires and study 
materials into the required languages for the participating sites. 
 
 Preparation of the participating clinical sites for the use of ASyMS through assessment 
of infrastructure and human and material resource requirements. 
 
 Testing and assessment of the technological readiness of the ASyMS system at the 
participating sites prior to commencing the randomised controlled trial.  
 
Logged data were used to assess the technological readiness of ASyMS across multiple 
sites, prior to its use in the main RCT.  These assessments included: clinician initial 
response times to alerts, clinician handling times of alerts, and technical issues reported 
in the support platform for the intervention. All data were    ǯ
secure researcher database hosted by the study technological partner, Docobo. Figure 2 
illustrates the Alert Generation and Handling System.  
Technological readiness was evaluated and confirmed using two Technological 
Feasibility Evaluation forms developed by the study investigators - one for clinicians 
(Appendix A) and one   ǯ  partner (Appendix B) who was 
responsible for maintaining the ASyMS system. On completion of the testing phase at each 
clinical site, a representative from the clinical site and technological partner were each 
required to complete their respective assessment.  
The three key parameters, derived from the technological requirements set out in the 
Study Protocol were included in both assessments, namely: 
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1. System Set-Up: to assess whether clinicians and researchers involved in the study 
felt they had received sufficient training on the ASyMS system; were able to 
register participants to use the ASyMS system (using handset, tablet, and PC) and 
were confident to educate and register a new patient on a handset. Each research 
nurse, clinician, and research assistant involved in the study was provided with 
training on the nature and use of the ASyMS system. This training included 
education regarding how the ASyMS system works, patient registration, and alert 
handling. Once trained, they were setup and registered on the ASyMS system with 
the appropriate functions of patient registration and alert handling. Each clinical 
site was given the option of individual logins for their users or a generic login to 
use the system.    
 
2. Data transfer: to assess whether data were successfully transferred among: 
electronic clinical and demographic patient data; patient devices; tablets 
collecting PROM data and electronic clinical case note reviews and the study 
server. It was essential that all devices involved in the study (i.e., patient devices, 
clinician handsets, tablets) had the required mobile or Wi-Fi connectivity for the 
intervention to be safe and effective. Prior to the testing period, the study 
technology partner conducted technological connectivity assessments of all 
devices at each clinical site. This testing required that clinicians carried the device 
over the course of a week and rotated the device amongst staff members taking 
part in the study, to determine any technological issues and potential areas in the 
hospital where the phone did not work or connect.  
 
 
3. Usability issues: to assess whether clinicians could access and log onto the ASyMS 
website to ensure timely and problem-free access, and their ability to log on and 
use the ASyMS clinician handset for the receipt of alerts as well as handling a 
patient generated alert using the ASyMS website. Clinicians were evaluated on 
their ability to use the clinician handset, log onto the ASyMS clinician website, 
handle patient alerts and complete medical reviews at     ǯ 
chemotherapy cycle. Clinicians were evaluated on their ability to use the ASyMS 
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technical support system if there were any technological issues encountered, from 
both clinician and patient perspectives.  
 
Following the evaluation of each site, the Principle Investigator at the clinical site 
received a formal letter from the Chief Investigator informing them of their positive 
evaluation and permitting their progression into the RCT. The authors of this paper 
would encourage researchers to use or adapt these checklists (Appendix A and B) to 
deploy digital health interventions. Copies of these checklists are available from the 
corresponding author (RM).  
 
Results  
Adapting the ASyMS intervention for European setting 
 
Scoping Review 
To standardise the ASyMS intervention across Europe, a scoping review was undertaken 
to ensure that the intervention was evidence-based and consistent with international, 
national, and relevant local guidelines for assessing and managing the most common 
chemotherapy-related symptoms [26].  
Following the completion of the scoping review, a consultation exercise was undertaken 
with clinicians (clinical advisory group) and patients (patient advisory group) at the 
participating clinical sites. This approach aligns with evidence that found the inclusion of 
clinician and patient consultation is more likely to lead to research that will translate into 
clinical practice [27, 28]. Patient and clinician advisory groups informed the content of 
the symptom questionnaires, symptom protocols, clinical algorithms, and self-care 
advice to ensure consensus across the multiple European clinical sites. The review of 
literature combined with feedback from clinician and patient advisory groups provided 
valuable information which enabled agreement amongst study partners on the format 
and content of the intervention, as well as making it current, evidence-based, and 
culturally sensitive.  
Additionally, to facilitate the development and refinement of the intervention, monthly 
videoconferences were held with all ASyMS study partners and investigators to provide 
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an opportunity to update, assess progress, and identify any issues within partner 
countries. These teleconferences facilitated open discussions and actions around issues 
including ethics and governance, data protection, study instruments, technology 
development and language translation processes. Likewise, clinicians and researchers 
committed to monthly teleconferences at this early stage and throughout the feasibility 
trial to discuss practical and clinical issues. 
 
Translation of study tools and related documentation  
A substantial methodological challenge for cross-cultural research is the standardization 
of the research instruments, particularly the translation of instruments without losing 
the underlying context or cultural connotations of the wording [15, 29, 30]. This process 
is often time consuming, but a crucial investment in order to have confidence in the 
outcomes of the study [30]. 
 
In order for ASyMS to be adapted and implemented within the various European 
countries, it was essential for all relevant documents to be translated into the appropriate 
languages (German, Greek, Norwegian). The two key components of the process were: 
(a) translation and linguistic validation of questionnaires (where appropriate) into 
the required languages for the participating sites; 
(b) translation of all additional study components and supporting documentation into 
the required languages (e.g., patient information letters, consent forms). 
We evaluated four companies, which fulfilled the following criteria for consideration: 
(a) compliance with International Society for Pharmacoeconomics and Outcomes 
Research (ISPOR) translation/validation guidelines; 
(b) prior experience in the translation/validation of patient-reported outcome 
measures as documented through previous collaborations/completed projects; 
(c) documented reliability/trustworthiness based on testimonials; and  
(d) acceptable costs and turnaround times to ensure project cost-effectiveness. 
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The chosen company to translate and linguistically validate the ASyMS study 
questionnaires was based on their robustness of their approach and costs.The translation 
of the ASyMS intervention content involved three translation rounds and interviews with 
lay people in the respective countries (Austria, Greece, Norway) in  accordance with 
current guidelines outlined by the ISPOR [31]. For each component of the ASyMS, the IT 
interface and documentation were adapted and translated for clinical use. Once the 
intervention content was translated and validated, ethical approval was obtained from 
the relevant ethics committees in all of the clinical sites across the five participating 
countries, detailed in our previous publication [25]. 
 
Preparation and readiness of clinical sites for RCT 
Prior to the use of the ASyMS during the eSMART trial the system was tested for readiness 
at each participating site before being deployed in the RCT.  
Participants 
A total of thirteen clinical sites within five European countries (i.e. Austria, Greece, 
Ireland, Norway, United Kingdom) were tested for readiness. During this testing phase a 
total of 64 patients consented to use the ASyMS system over one cycle of chemotherapy.  
At each site, two patients per cancer type (not all sites included all three patient 
populations) were recruited to test the intervention. Inclusion and exclusion criteria are 
detailed in Textbox 1, while patient numbers per diagnosis at the different European sites 
are shown in Table 1 respectively.  
 
Textbox 1. Participant eligibility inclusion criteria  
Inclusion Criteria 
x ȋ ? ? ?Ȍ 
x    ǡ  ǡ ǯ ǡ   
Lymphoma 
x Currently receiving or about to start first-line chemotherapy 
x Scheduled to receive 2, 3, or 4 weekly chemotherapy protocols (i.e., chemotherapy 
administered every 14, 21, or 28 days, respectively) 
x Scheduled to receive one cycle of chemotherapy 
x Physically/psychologically fit to participate in the study  
x Able to understand and communicate in the respective language 
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Exclusion Criteria 
x Diagnosed with a distant metastasis in the case of breast cancer or colorectal cancer  
x         ǯ   -Hodgkin 
Lymphoma diagnosis 
x Scheduled to receive concurrent radiotherapy 
x Scheduled to receive weekly chemotherapy 
x Diagnosed with recurrent cancer  
x Patients who have had chemotherapy within the previous 5 years for any medical 
reason 
x Unable to provide written informed consent 
 
Table 1. Number of patients recruited to conduct feasibility study at each clinical site 
Study Centre  Breast Colorectal Haematological 
Site 1: Austria 2 2 2 
Site 2: UK 2 2 1 
Site 3: UK 2 2  
Site 4: UK 2 2 2 
Site 5: UK 2 2 2 
Site 6: Greece 2 2  
Site 7: Greece 2 2  
Site 8: Greece 2 2 2 
Site 9: Ireland  2 2  
Site 10: Ireland 2 2  
Site 11: Ireland 2 2 2 
Site 12: Ireland 2 2 1 
Site 13: Norway 2 2  
Total 26 26 12 
 
 
Connectivity and communications  
Prior to the selection of each site to participate in the RCT and during the testing phase, 
the reliability of Wi-Fi and mobile data networks were assessed at each site. This 
evaluation was done by the technology partner, Docobo, using a Connectivity Logger 
application which was run on Motorola Moto-g devices at each of the participating sites.  
The Connectivity Logger application measured and logged the quality of mobile and/or 
Wi-Fi networks at one minute intervals while the device was being carried by a clinician 
during their working hours. The application was able to identify any physical areas in a 
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clinical site where the device could not access Wi-Fi or a mobile data network. The 
connectivity information was sent to the technological partner for analysis. Clinicians 
were required to log at least 12 hours of mobile data and Wi-Fi, if it was available at their 
clinical site. While some sites were able to acquire only the minimum data requested, 
some were able to collect very large volumes of data.  
The primary criteria for this assessment used was the maximum sustained period for 
which no communication over the mobile network (that is neither mobile IP or text 
communications) were possible, being no more than 15 minutes (target response time 
was 30 minutes). Secondary factors considered were the distribution of signal strength 
and the quality of the mobile data connection. Analysis showed that at most sites, the 
connectivity environment was favourable in providing a reliable communication channel 
to the clinician device. However, one clinical site had a loss of connectivity for up to 20 
minutes (based on 800 hours of testing), compared to other clinical sites who had 
between 5 and12 minutes of disconnection. 
To resolve this issue, a member of the Docobo team visited the clinical site to investigate 
the cause of the interruption. Based on their visit and Connectivity Logger data, Docobo 
concluded that the disconnection occurred in the corridors of the clinical site, not on the 
relevant oncology ward, which had suboptimal connectivity which forced the handset to 
connect to a weak mobile network. Given the potential impact on clinical care should an 
alert not be received by a clinician on time ǡǯ
concluded that all clinician handsets needed to monitor for and make clinicians aware of 
a loss of network connectivity. They implemented changes in the ASyMS system which 
could monitor the clinician device at all times and make clinicians aware, via automated 
SMS and email, when a handset has lost connectivity. Their analysis showed that two 
active devices were needed at each clinical site, with one in-use and the second on-charge, 
to allow for efficient charging and ensuring that clinicians could hold the device with 24 
hour coverage as required.  
 
Adherence and acceptability 
Data regarding the usability of ASyMS were collected and consolidated by the study 
technology partner and analysed by the relevant study work package Leads (EF, PF, AD). 
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Across all sites, 86% of the patients who were eligible agreed to participate (see Figure 1 
for flow of patients through the study). Reasons for declining to participate included 
being too busy, fears that study involvement would increase worry and stress levels due 
to thinking more about their diagnosis, and concerns about using technology. At an 
organisational level, it was notable that of the thirteen sites that completed the feasibility 
study, two reported the intervention was not feasible to integrate into their clinical 
practice, (i.e., one site in the United Kingdom and one in Ireland). The reason for their 
decision was due to the management and related alert handling responsibilities of the 
system outside the normal working day.  
Of those who enrolled, adherence to the protocol was high with 96% of the patients 
completing the testing phase. Two patients withdrew from the feasibility study: one 
because of technical difficulties and the other because their chemotherapy treatment was 
discontinued. 
 
Figure 3. Patient recruitment 
 
Completion of the daily symptom questionnaire on the mobile device was high overall, 
with patients using it 87.4% of the time. No statistically significant differences in 
adherence rates were found across countries: (United Kingdom = 83%; Ireland = 90%; 
Norway = 86.3%; Greece = 86.7%; Austria = 97%; (p = .154) (See Figure 3). Similarly, no 
differences were found in the adherences rates for completing the daily questionnaire by 
cancer type (breast cancer = 87.5%, colorectal cancer = 90.3% and haematological 
cancers =80.6% (p = .477) (See Figure 4).  
 
 
 
 
 
 
Table 2. Compliance of daily questionnaire by country.  
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Data are plotted as means ± 1 standard error  
 
Figure 3. Completion of questionnaire by cancer type 
 
Data are plotted as means ± 1 standard error 
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Alert handling 
Across all thirteen European sites, during the testing phase, a total of 157 amber and 139 
red alerts were generated by the 64 patients during one cycle of chemotherapy. Patients 
with haematological cancers generated an average of 1.25 red alerts per person, those 
with colorectal cancer had an average of 2.3 red alerts; and those with breast cancer had 
2.4 red alerts. Amber alerts followed a similar pattern: patients with haematological 
cancers generated an average of 2.6 amber alerts, those with colorectal cancer had an 
average of 2 amber alerts, and those with breast cancer had 2.8 amber alerts.  
On average, it took 38.26 minutes (SD=138) to handle an amber alert and 15.7 minutes 
(SD=20) to handle a red alert. During the monthly trial management meetings, clinicians 
and researchers across all five countries agreed that the timeframe for handling amber 
alerts (i.e. mild to moderate patient symptoms) should be changed from 4 to 8 hours. In 
addition, clinicians recommended modifications to the ASyMS algorithm regarding the 
symptom of mucositis (i.e., painful inflammation and ulceration of the mouth and throat). 
During the testing period, it became apparent that clinicians were receiving numerous 
alerts from patients about mucositis. These alerts occurred because, even with prompt 
and appropriate interventions, mucositis takes time to improve. Consequently, patients 
reported this symptom over multiple days which triggered an alert to the clinician based 
on our clinical algorithm. This alert continued to occur even though patients had 
triggered this alert and been contacted and given appropriate information and 
interventions. The subsequent telephone contact between clinicians and patients was 
reported as both anxiety-inducing for the patient (e.g., some were worried that they were 
triggering alerts despite performing the recommended self-care interventions) and time 
consuming for clinicians (who had already given the patient appropriate symptom 
advice). This algorithm was modified that while clinicians were    ǯ
initial report of mucositis, depending on the severity of the mucositis subsequent alerts 
would  Ǯǯ     s, allowing time for the intervention time to 
improve the mucositis. These modifications required technical changes in the ASyMS 
system and subsequent simultaneous ethical submissions at all clinical sites in order to 
implement the change.  
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Technical Issues 
ASyMS has a dedicated online support platform for clinicians and researchers to report 
technical problems and have them solve these problems. This technical support platform 
allowed users to log, solve, and track issues that arose during the feasibility study. This 
approach facilitated rapid and tailored responses, as well as acting as a record of 
correspondence on the technological issues. During the testing phase, a total 112 issues 
were logged, the most common being difficulties using the clinical server (32.25%), 
which is the online platform for clinicians and researchers to enrol patients, handle alerts 
and monitor trial progress. In addition, 25% of the issues were related to the clinician 
handset and 18.8% were related to the patient device. These issues were rectified at each 
site, through investigation by the technology partner and additional training on using the 
system, before progression to the main trial. 
 
Process to confirm and check readiness to participate in RCT 
When each site completed the testing period, they were assessed for their readiness to 
move onto the RCT. This evaluation was done using the Technological Feasibility 
Evaluation Checklists (Appendix A and B). Across the thirteen sites, eleven sites 
successfully passed the technological feasibility evaluation to participate in the RCT.  Of 
the two sites who did not proceed to the RCT, one was not assessed with the checklist as 
they did not achieve the required recruitment number of patients for the feasibility study 
(n=6). Their decision to withdraw from research was due to lack of staffing resources to 
undertake 24 hour clinician alert handling. Despite several attempts, it was decided that 
this clinical site did not have the capacity to recruit more participants and therefore could 
not implement ASyMS effectively. A second site did not pass the readiness screening for 
a variety of reasons including: ongoing connectivity issues to the mobile network, user 
issues with the registration of new patients to ASyMS systemǡǯ to 
log onto the ASyMS system in a timely manner to handle alerts. Following discussions 
with the clinical site and the ASyMS research team, the decision was made not to include 
the site as part of the RCT. 
Of the eleven sites that moved on to participate in the RCT, a number initially had 
discrepancies between reports by the technology company and reports by the clinical 
sites. Discrepancies included issues with Wi-Fi/mobile connectivity issues, local firewall 
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regulations, ǯ log-ins, patient enrolment, and completion of patient case note 
reviews. These issues were investigated and resolved by the researchers at University 
College Dublin (AB, AD). Each unique issue required individualised attention and partner 
involvement to resolve. For example, a local firewall regulation that obstructed the 
technology from using a local WiFi/mobile network connection required that clinicians 
seek help from their local IT department.  At another site the technology company need 
to assist with the installation of software on the mobile devices. When issues arose with 
logging on to the system and patient enrolment and alert handling, clinicians were 
provided with follow-up training sessions to allow them to ask questions and ensure they 
had the knowledge and skills to use the system. Once each site had satisfactorily 
completed all of the required components and were verified by the technology company, 
the Chief Investigator signed off on the site as being ready to start the RCT.  
 
Discussion  
The aim of this study was to describe the processes undertaken in the preparation of an 
international multi-centre randomised controlled trial and to provide the results of the 
feasibility study. The successful adaptation of the ASyMS intervention is evident via 
implementation in thirteen cancer clinical practices across five European countries (i.e., 
Austria, Greece, Ireland, Norway, United Kingdom). Implementation was achieved 
through collaborative work with study partners and the implementation of an iterative 
process to resolve problems in each clinical site.  Use of the Technological Feasibility 
Evaluation Checklists (Appendices A and B) provided valuable quality assurance across 
all clinical sites.  The undertaking of cross-cultural and multi-centre research requires 
several considerations to address the complexities involved in capturing electronic data 
[32], and researchers in this study faced diverse and unique challenges. The time needed 
to ensure the European integration in preparation for the feasibility study was significant. 
While the intervention was based on preliminary in the United Kingdom [11], the revision 
of the intervention to make it applicable across our European sites involved significant 
input. A systematic review [26] of the international evidence on the management of 
chemotherapy induced toxicity was done. The ASyMS patient survey, risk algorithm, and 
alert management design were refined based on this scoping review. Moreover, the 
content of the ASyMS intervention had to reflect not only current international standards 
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identified in the scoping review; it had to be delivered in the appropriate language. All 
study documentation, including the electronic assessments, had to be translated from 
English into Greek, Norwegian, and German. This rigorous process involved multiple 
iterations and tests of linguistic validity, which was time consuming and costly, a finding 
which is supported by McIntosh et al. 2016 [24]. Nevertheless, effective and culturally 
sensitive translation was vital to ensure the intervention was appropriate for its intended 
users in each European country.  
The testing phase was a crucial step in the transition from adaptation to implementation. 
This highlighted additional areas where the technology needed to be adapted in order to 
meet the diverse needs of the users (i.e., clinicians, patients). Following the identification 
of a number of clinical and technical key issues, the intervention was refined and updated 
to reflect feedback provided by clinicians, researchers, and IT support. One of the most 
significant outcomes of the testing phase was the establishment of relationships and 
communication between the ASyMS research team and the clinical teams at each site, a 
theme that also supported in McIntosh et al. (2016) findings [24]. The establishment of 
relationships between teams facilitated  ǯ     
patients, as well as establish rapport with clinicians who would assist with recruitment. 
In addition, clinician became familiar with the study protocol and procedures. Based on 
previous research that showed clinicianǯ concern and apprehension about new eHealth 
technologies [33-35], the testing of ASyMS helped the research team identify cliniciansǯ
concerns and provide additional training sessions that afforded clinicians the 
opportunity to learn about the ASyMS protocol, express their concerns, and ask questions 
about the technology.  
A number of changes were made to the patient questionnaire, the risk algorithm, and the 
alert management system. The clinical risk algorithm for ASyMS was amended to reflect 
current clinical guidelines and feedback from the clinician advisory group regarding the 
fever threshold for a red alert. In addition, the self-care library available on the ASyMS 
patient device was updated based on feedback from clinicians and patients [26].  
The trial management group meetings, which were held monthly during the feasibility 
trial, identified that a 4 hour response requirement to manage was not feasible in busy 
oncology units and that the algorithm for mucositis warranted modification.  These issues 
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with the ASyMS algorithms were only apparent when it was implemented in multiple 
clinical sites. In addition, our feasibility testing allowed us to identify sites that were not 
appropriate for the RCT because of heavy workload and views that the intervention was 
too complex. These findings echo the importance of testing an intervention in different 
contexts, as well as the establishment of communication pathways that clinicians and 
researchers can use to gain first-hand experience about the intervention [36].  
The findings from the testing phase showed that the intervention was applicable and 
acceptable to both patients and clinicians. ǯ with cancer were able to use the 
ASyMS intervention to complete the daily questionnaire and access self-care information. 
Prior studies have explored mechanisms by which patient reporting of symptoms may 
confer clinical benefits and enhance symptom management [5]. The 64 patients in five 
European countries, from three different diagnostic groups, consented to use the eHealth 
device over one cycle of chemotherapy. Patient adherence was high and alert activation 
and handling results were similar to previous ASyMS studies conducted among patients 
with a variety of cancers [11, 17, 37, 38]. Our testing phase should be interpreted in the 
context of two key limitations in that patients were not recruited prior to the initiation of 
chemotherapy. Therefore, some patients were chemotherapy naïve and others had 
received previous chemotherapy treatments which may have affected the results of the 
daily questionnaire data.  However, despite these limitations, our work provided 
significant data around feasibility, changes needed for future use, and the perceived 
benefits of such a system in oncology units.  
 
Conclusion 
Patients with cancer undergoing chemotherapy require prompt identification of 
symptoms and interventions are needed to decrease the symptom burden and enhance 
quality of life. eHealth interventions can assist with the promotion of self-care skills to 
manage the side effects of chemotherapy and provide an immediate electronic 
connection with the clinicians.  However, the development and deployment of such a 
system demands significant and substantial collaborative preparatory work across 
multinational settings. The issues and findings discussed in this paper outline the 
importance of effective collaborative project management, diligent use of checklists, clear 
division of responsibilities with each partner, country, and associated clinical sites, along 
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with addressing cultural and language requisites so that the scientific integrity and 
reproducibility of the study is assured.  
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Appendix A: eSMART Study Procedure Ȃ Feasibility Evaluation Checklist for 
Clinicians 
Clinical Site 
 
Parameters of Effectiveness Feasibility Parameters (Part 1) 
Please complete this form and send it to glasgow-esmart@strath.ac.uk and 
andrew.darley@ucd.ie  
 
Have each of the following been completed satisfactorily?  Y/N 
Setup 
 
Training of research nurse / assistant to use ASyMS 
 
Registration of clinicians on ASyMS  
 
 
 
Patient related  
Registration of patients on ASyMS   
Transfer of data from patient handset to study server (successful 
connectivity indicated by a green segment in the connectivity history bar) 
 
 
 
Connectivity  
Technological connectivity of ASyMS (mobile connectivity/Wi-Fi/other) - 
clinician handsets 
 
Technological connectivity of ASyMS (mobile connectivity/Wi-Fi/other) Ȃ 
tablets 
 
Technological connectivity of ASyMS (used wireless/wired network 
connectivity) - system 
 
 
 
Clinician related  
Patients registered on the server have become available on the PROM 
terminal 
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Completion of electronic PROM data by patients and successful transfer to 
study server 
 
Completion of electronic Case Note Review data and successful transfer of 
to study server 
 
  
Support system  
Have been able to login to the eSMART support system  
 
ǲǳǡdetails: 
 
 
 
 
 
 
 
 
 
 
Please sign and date form on page 2 
 
 
All clinical sites that meet the afore-mentioned requirements will proceed to Part 2. 
Docobo name and signature: 
 
Date: 
 
University College Dublin Researcher name and 
signature: 
 
Date: 
CI name and signature: 
 
Date: 
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Appendix B: eSMART Study Procedure ȂTechnological Feasibility Evaluation 
Checklist 
 
Appendix B 
Clinical Site: 
PI: 
 
Parameters of Effectiveness Feasibility Parameters (Part 1) 
Please complete this form and send it to glasgow-esmart@strath.ac.uk and 
andrew.darley@ucd.ie 
 
Have each of the following been completed satisfactorily?  Y/N 
Setup 
 
Training of research nurse / assistant to use ASyMS 
 
Training of clinicians to use ASyMS 
 
Registration of clinicians on ASyMS  
 
 
 
Patient related  
Registration of patients on Promasys  
Training of patients to use ASyMS  
Registration of patients on ASyMS   
Completion of electronic clinical and demographic patient data and successful 
transfer to the study server 
 
Registration of patients on patient device  
Use of patient device (completion of symptom questionnaire, access to self-
care, access to symptom graphs, library, useful contacts, visibility/speech 
setting) by patients 
 
 
 
Connectivity  
Technological connectivity of ASyMS (mobile connectivity/Wi-Fi/other) - 
patient devices 
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Technological connectivity of ASyMS (mobile connectivity/Wi-Fi/other) Ȃ 
clinician handsets 
 
Technological connectivity of ASyMS (mobile connectivity/Wi-Fi/other) Ȃ 
tablets 
 
 
 
Clinician related  
Ability of clinicians to log on and use ASyMS clinician handset for the receipt of 
alerts 
 
Ability of clinicians to access and log onto the ASyMS web-portal  
Ability of clinicians to deal with an alert using the ASyMS web portal  
Completion of electronic PROMs (pre- and post-CTx assessments) by patients 
and successful transfer to study server  
 
Completion of Case Note Review and successful transfer to study server  
 
 
Support system  
Ability to access/use the eSMART support system  
 
ǲǳǡdetails on 
page 2: 
 
Please sign and date form on page 2 
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ǲǳǡǣ 
 
 
 
 
 
 
 
 
 
 
 
All clinical sites that meet the afore-mentioned requirements will proceed to Part 2. 
PI name and signature: 
 
Date: 
 
University College Dublin Researcher name and 
signature: 
 
Date: 
 
CI name and signature: 
 
Date: 
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